Artios Pharma Ltd has negotiated its second major collaboration in four months for the use of its DNA damage response technology to help a partner develop new drugs for cancer. The newest deal is with Novartis, which has agreed to pay the UK company $20 million upfront for access to the platform as well as research funding and up to $1.3 billion in discovery, development, regulatory and sales-based milestone payments.
